Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Gynecological Cancer × anlotinib × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 25 Small Cell Lung Carcinoma 12 Sarcoma 8 Breast Neoplasms 8 Lung Neoplasms 6 Neoplasms 5 Esophageal Squamous Cell Carcinoma 5 Carcinoma, Hepatocellular 5 Stomach Neoplasms 4 Pancreatic Neoplasms 4 Ovarian Neoplasms 4 Carcinoma 4 Triple Negative Breast Neoplasms 3 Thyroid Neoplasms 3 Nasopharyngeal Carcinoma 3 NSCLC 3 Glioma 3 Colorectal Neoplasms 3 Carcinoma, Renal Cell 3 Uterine Cervical Neoplasms 2 Urogenital Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Recurrence 2 Platinum-resistant Ovarian Cancer 2 Pheochromocytoma 2 Paraganglioma 2 Ovarian Diseases 2 Neoplasms, Glandular and Epithelial 2 Neoplasms by Site 2 Neoplasms by Histologic Type 2

Interventions

penpulimab 1 anlotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05028504 2023-12-27

ALTER-GO-020

Sichuan Cancer Hospital and Research Institute

Phase 2 Unknown

Gynecological Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡